Despite these obstacles, CD33-targeted CAR T-cell therapy remains an area of active investigation, with efforts directed toward refining its clinical applicability in high-risk TP53-mutated AML and MDS. This evidence concerns the gene CD33 and myelodysplastic syndrome.